A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 19, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
DRUG

WVE-006

RNA editing oligonucleotide

Trial Locations (9)

3065

RECRUITING

St. Vincent's Hospital, Melbourne, Fitzroy

3204

RECRUITING

Waikato Hospital, Hamilton

20520

RECRUITING

Turku University Hospital, Turku

52074

RECRUITING

Universitaetsklinikum Aachen, AoeR, Aachen

B3H 1V7

RECRUITING

Dalhousie University - Queen Elizabeth II Health Sciences Centre, Halifax

M5T 3A9

RECRUITING

Inspiration Research Limited, Toronto

B15 2GW

RECRUITING

Queen Elizabeth Hospital, University Hospital Birmingham, Birmingham

CB2 0QQ

RECRUITING

Cambridge University - Addenbrooke's Hospital, Cambridge

SW8 3RN

RECRUITING

Royal Free London NHS Foundation Trust, London

All Listed Sponsors
lead

Wave Life Sciences Ltd.

INDUSTRY